课题基金 / 基金详情

GENETICALLY ENGINEERED HSV 1 IN MALIGNANT GLIOMA

GENETICALLY ENGINEERED HSV 1 IN MALIGNANT GLIOMA
恶性胶质瘤中的基因工程 HSV 1
批准号：
6302991
负责人：
JAMES M MARKERT
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6302991
关键词：
clinical research gene therapy genetic manipulation glioma herpes simplex virus 1 human subject human therapy evaluation magnetic resonance imaging neoplastic growth transfection /expression vector

项目摘要

项目成果

JAMES M MARKERT的其他基金

相似基金

相关文献

中文摘要
翻译
目的是确定递增剂量G207病毒的单次和多次立体定向脑内注射的安全性和耐受性及其对复发性恶性胶质瘤患者的潜在益处。除了队列7（最后一个队列）将接受7次注射外，所有剂量水平都将使用一次注射。
英文摘要
The purpose is to determine the safety and tolerability of single and multiple stereotactic intracerebral injection(s) of escalating doses of G207 virus and its potential benefits in patients with recurrent malignant gliomas. A single injection will beused for all dosing levels except cohort 7, the last cohort, which will receive 7 injections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma
Lessons from the OR: Using Clinical Biologic Correlates to Inform HSV Trial
Lessons from the OR: Using Clinical Biologic Correlates to Inform HSV Trial
CT 2001 A STAGED PHASE I STUDY OF THE TREATMENT OF MALIGNANT GLIOMA WITH G207,
海外基金